ShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development

SAN FRANCISCO, May 24, 2017 /PRNewswire/ -- ShangPharma Innovation (SPI) today announced the appointment of Mohamad Moghadam-Tabrizi to the position of Senior Vice President, Business Development.

Mr. Tabrizi previously served in senior and executive level positions in corporate business development at Nektar, investor relations and corporate communications at Depomed, healthcare investment banking at Needham, RBC Capital Markets, and Merrill Lynch, and as CFO at Alacritas (Omnicare). In these roles, Mohamad led numerous deals spanning the range of royalty monetization, out-licensing and in-licensing, manufacturing and supply, collaborations and partnerships, mergers and acquisitions, and public and private financings including roadshows and venture investments.

"We are very pleased to welcome Mohamad to ShangPharma Innovation. He is a highly successful professional with broad transaction expertise in all aspects of business and corporate development in the biopharmaceutical industry — financial, investor, licensing, strategic, and more," said Walter H. Moos, CEO of SPI.

Earlier in his career, Mohamad was a researcher at the Howard Hughes Medical Institute, Stanford University Medical School, and Systemix. He received his undergraduate and graduate training in genetics and biological sciences at the University of California Davis and Stanford University and an MBA from Cornell University.

Mohamad will aid in the achievement of key objectives at SPI which include facilitating and accelerating drug discovery with a focus on therapeutics and platform technologies, and also offering funding, other support, and incubator space to entrepreneurial partners. These partnerships include proof-of-concept research at academic and major medical centers, research institutes, and early-stage start-ups with the goal of achieving industry collaborations and/or venture capital financing.

FOR MORE INFORMATION 

ShangPharma Innovation, Inc.
[email protected]

SOURCE ShangPharma Corporation